Rocket


News + Filings
Transactions
Holdings



Pontifax Management 4 G.P. (2015) Ltd.

DateNameSymbolTypeSecuritySharesPriceValueOwnershipReported
11/29/2022Keros Therapeutics, Inc.KROSExercise (in-the-money or at-the-money)Call Options (obligation to sell)3.5k$0.00$0.4See footnote11/29/2022
11/29/2022Keros Therapeutics, Inc.KROSExercise (in-the-money or at-the-money)Call Options (obligation to sell)1.7k$0.00$0.2See footnote11/29/2022
11/29/2022Keros Therapeutics, Inc.KROSExercise (in-the-money or at-the-money)Call Options (obligation to sell)1.9k$0.00$0.2See footnote11/29/2022
05/13/2021Eloxx Pharmaceuticals, Inc.ELOXPurchaseCommon Stock1.3M$1.35$1.7MBy Pontifax Investment Fund05/13/2021
05/13/2021Eloxx Pharmaceuticals, Inc.ELOXPurchaseCommon Stock2.6M$1.35$3.6MBy Pontifax Investment Fund05/13/2021
05/13/2021Eloxx Pharmaceuticals, Inc.ELOXPurchaseCommon Stock1.4M$1.35$1.9MBy Pontifax Investment Fund05/13/2021
05/13/2021Eloxx Pharmaceuticals, Inc.ELOXPurchaseCommon Stock592.6k$1.35$800kBy Pontifax Investment Fund05/13/2021
11/17/2020Keros Therapeutics, Inc.KROSPurchaseCommon Stock26.6k$50.00$1.3MSee footnote11/17/2020
11/17/2020Keros Therapeutics, Inc.KROSPurchaseCommon Stock13k$50.00$648.3kSee footnote11/17/2020
11/17/2020Keros Therapeutics, Inc.KROSPurchaseCommon Stock14.4k$50.00$720kSee footnote11/17/2020
11/17/2020Keros Therapeutics, Inc.KROSPurchaseCommon Stock6k$50.00$300kSee footnote11/17/2020
05/20/2020Eloxx Pharmaceuticals, Inc.ELOXGrantStock Option (Right to Buy)20k$3.39$67.8kSee Footnote05/20/2020
05/20/2020Eloxx Pharmaceuticals, Inc.ELOXGrantStock Option (Right to Buy)20k$3.39$67.8kSee Footnote05/20/2020
04/13/2020Keros Therapeutics, Inc.KROSConversionCommon Stock1.4M$0.00$0See footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSConversionCommon Stock663.8k$0.00$0See footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSConversionCommon Stock737.2k$0.00$0See footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSConversionCommon Stock169.3k$0.00$0See footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSConversionCommon Stock82.4k$0.00$0See footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSConversionCommon Stock91.5k$0.00$0See footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSConversionCommon Stock68.7k$0.00$0See footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSConversionCommon Stock163.6k$0.00$0See footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSConversionCommon Stock88.5k$0.00$0See footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSConversionCommon Stock79.7k$0.00$0See footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSConversionCommon Stock36.9k$0.00$0See footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSPurchaseCommon Stock194.2k$16.00$3.1MSee footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSPurchaseCommon Stock94.5k$16.00$1.5MSee footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSPurchaseCommon Stock105k$16.00$1.7MSee footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSPurchaseCommon Stock43.8k$16.00$700kSee footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSConversionSeries A Preferred Stock1.4M$0.00$0See footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSConversionSeries A Preferred Stock663.8k$0.00$0See footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSConversionSeries A Preferred Stock737.2k$0.00$0See footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSConversionSeries B-1 Preferred Stock169.3k$0.00$0See footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSConversionSeries B-1 Preferred Stock82.4k$0.00$0See footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSConversionSeries B-1 Preferred Stock91.5k$0.00$0See footnote04/13/2020
04/13/2020Keros Therapeutics, Inc.KROSConversionSeries B-1 Preferred Stock68.7k$0.00$0See footnote04/13/2020
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy